Clinical Stage Programs
Program
MOA
Indications
IND
Phase I
Phase II
Phase III
Rights
LM-302
Anti-Claudin18.2 ADC
3L+ GC/GEJ
Global available
LM-302
Anti-Claudin18.2 ADC
1L GC/GEJ
Global available
LM-302
Anti-Claudin18.2 ADC
PDAC
Global available
LM-108
Anti-CCR8 mAb
MSI-H tumors
ex-China available
LM-108
Anti-CCR8 mAb
2L GC/GEJ
ex-China available
LM-101
Anti-SIRPα mAb
Solid tumors & hematologic malignancies
Global available
LM-305
Anti-GPRC5D ADC
Multiple Myeloma
AstraZeneca (Global)
LM-24C5
CEACAM5 BsAb
CRC, GI cancer, lung cancer
Global available
LM-299
anti-PD-1 x anti-VEGF BsAb
Solid tumors
MSD (Global)
LM-168
Anti-CTLA4 (TME specific)
Solid tumors
Global available
LM-2417
Anti-NaPi2b BsAb
Lung cancer, ovarian cancer
Global available
Clinical Stage Programs
LM-302
3L+ GC/GEJ
IND
Phase I
Phase II
Phase III
MOA
Anti-Claudin18.2 ADC
Rights
Global available
LM-302
1L GC/GEJ
IND
Phase I
Phase II
Phase III
MOA
Anti-Claudin18.2 ADC
Rights
Global available
LM-302
PDAC
IND
Phase I
Phase II
Phase III
MOA
Anti-Claudin18.2 ADC
Rights
Global available
LM-108
MSI-H tumors
IND
Phase I
Phase II
Phase III
MOA
Anti-CCR8 mAb
Rights
ex-China available
LM-108
2L GC/GEJ
IND
Phase I
Phase II
Phase III
MOA
Anti-CCR8 mAb
Rights
ex-China available
LM-101
Solid tumors & hematologic malignancies
IND
Phase I
Phase II
Phase III
MOA
Anti-SIRPα mAb
Rights
Global available
LM-305
Multiple Myeloma
IND
Phase I
Phase II
Phase III
MOA
Anti-GPRC5D ADC
Rights
AstraZeneca (Global)
LM-24C5
CRC, GI cancer, lung cancer
IND
Phase I
Phase II
Phase III
MOA
CEACAM5 BsAb
Rights
Global available
LM-299
Solid tumors
IND
Phase I
Phase II
Phase III
MOA
anti-PD-1 x anti-VEGF BsAb
Rights
MSD (Global)
LM-168
Solid tumors
IND
Phase I
Phase II
Phase III
MOA
Anti-CTLA4 (TME specific)
Rights
Global available
LM-2417
Lung cancer, ovarian cancer
IND
Phase I
Phase II
Phase III
MOA
Anti-NaPi2b BsAb
Rights
Global available
Preclinical Stage Programs
Program
MOA
Indications
Discovery
PCC
IND-enabling
Rights
LM-350
anti-CDH17 ADC
CRC, PDAC, GC
Global available
LM-364
Undisclosed ADC
NSCLC, HNSCC, UC
Global available
LM-338
Undisclosed ADC
CRC, NSCLC, GC
Global available
LM-359
Undisclosed ADC
HCC
Global available
LM-319
Undisclosed ADC
TNBC, lung cancer
Global available
LM-316
Undisclosed ADC
NSCLC, OC, TNBC
Global available
LM-339
Undisclosed ADC
NSCLC, OC
Global available
LM-2199
Undisclosed BsAb
NSCLC, CRC, HNSCC, GC
Global available
Clinical Stage Programs
LM-350
CRC, PDAC, GC
Discovery
PCC
IND-enabling
MOA
anti-CDH17 ADC
Rights
Global available
LM-364
NSCLC, HNSCC, UC
Discovery
PCC
IND-enabling
MOA
Undisclosed ADC
Rights
Global available
LM-338
CRC, NSCLC, GC
Discovery
PCC
IND-enabling
MOA
Undisclosed ADC
Rights
Global available
LM-359
HCC
Discovery
PCC
IND-enabling
MOA
Undisclosed ADC
Rights
Global available
LM-319
TNBC, lung cancer
Discovery
PCC
IND-enabling
MOA
Undisclosed ADC
Rights
Global available
LM-316
NSCLC, OC, TNBC
Discovery
PCC
IND-enabling
MOA
Undisclosed ADC
Rights
Global available
LM-339
NSCLC, OC
Discovery
PCC
IND-enabling
MOA
Undisclosed ADC
Rights
Global available
LM-2199
NSCLC, CRC, HNSCC, GC
Discovery
PCC
IND-enabling
MOA
Undisclosed BsAb
Rights
Global available
